Search results
Results From The WOW.Com Content Network
Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company based in Hyderabad, which is engaged in drug discovery, drug development, and the manufacture of vaccines, biotherapeutics, pharmaceuticals and healthcare products.
The company formulates over 12.5 crore doses of OPV and had aggregated revenues of ₹ 30.5 crore (equivalent to ₹ 98 crore or US$11 million in 2023) in fiscal 2006. [2] [3] BIBCOL is under the administrative control of the Department of Biotechnology, Ministry of Science and Technology.
Dr. Krishna Ella is an Indian scientist and entrepreneur.He is the founder and Executive Chairman of Bharat Biotech. [1] [2] Ella and his company were responsible for developing India's own COVID-19 vaccine, Covaxin, World's 1st clinically proven conjugated Typhoid Vaccine, TypbarTCV and ROTAVAC.
India's Bharat Biotech said on Tuesday its oral cholera vaccine cleared a late-stage trial and that it plans a global launch, aiming to make up to 200 million doses a year amid an expanding ...
Bharat Biotech is a pioneering biotechnology company known for its world-class research and development and manufacturing capabilities. As part of the collaboration, the companies will co-develop and commercialize AV0328 , a synthetic vaccine targeting poly N-acetyl glucosamine (PNAG), in India and other licensed territories.
The vaccine is produced with Bharat Biotech's in-house vero cell manufacturing platform [12] that has the capacity to deliver about 300 million doses. [13] The company is in the process of setting up a second plant at its Genome Valley facility in Hyderabad to make Covaxin.
iNCOVACC (codenamed BBV154) [1] is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [2] [3] American company Precision Virologics [4] [5] and the Washington University School of Medicine in St Louis, Missouri, United States. [6] [7]
During the COVID-19 pandemic, the company signed a pact with Baylor College of Medicine, Texas Children's Hospital and Dynavax Technologies to develop a COVID-19 vaccine. [6] [7] The vaccine Corbevax [8] /Bio E COVID-19 was expected to roll out in 2021 with 75 to 80 million doses manufactured per month; the production was expected to reach 1 billion doses by the end of 2022 under the Quad ...